What is Leerink Partnrs’ Forecast for AURA FY2025 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Investment analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for shares of Aura Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($1.98) per share for the year, down from their prior forecast of ($1.93). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ FY2026 earnings at ($2.27) EPS.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02.

A number of other analysts have also recently weighed in on AURA. BTIG Research raised their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 18th. Scotiabank lifted their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Finally, Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Trading Down 0.4 %

AURA opened at $7.73 on Monday. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The stock has a fifty day moving average price of $8.14 and a 200-day moving average price of $8.84. The firm has a market cap of $386.11 million, a price-to-earnings ratio of -4.47 and a beta of 0.29.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Aura Biosciences by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock valued at $15,764,000 after purchasing an additional 112,296 shares during the period. American Century Companies Inc. raised its stake in shares of Aura Biosciences by 33.9% during the 4th quarter. American Century Companies Inc. now owns 47,701 shares of the company’s stock worth $392,000 after buying an additional 12,081 shares during the period. Intech Investment Management LLC purchased a new position in shares of Aura Biosciences during the 4th quarter valued at approximately $172,000. AlphaQuest LLC acquired a new stake in Aura Biosciences in the 4th quarter valued at $136,000. Finally, Levin Capital Strategies L.P. increased its holdings in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after acquiring an additional 783,984 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,778 shares of company stock worth $240,706 over the last 90 days. 5.40% of the stock is currently owned by company insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.